Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-week, Multicentre, Observational, Prospective Study on the Use of a Smart Platform Connected to a Single-inhaler Triple Therapy (ICS/LABA/LAMA) to Evaluate Effectiveness on Treatment Adherence and Inhaler Technique in Patients With Poorly Controlled Asthma.

NCT06908421 is registered in ClinicalTrials.gov with Chiesi Pharma AB, Nordic as lead sponsor.

NCT NCT06908421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06908421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-week, Multicentre, Observational, Prospective Study on the Use of a Smart Platform Connected to a Single-inhaler Triple Therapy (ICS/LABA/LAMA) to Evaluate Effectiveness on Treatment Adherence and Inhaler Technique in Patients With Poorly Controlled Asthma.
Lead sponsor
Chiesi Pharma AB, Nordic
Phase
Observational
Overall status
Recruiting
Start date
September 15, 2025
Completion date
September 30, 2027
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

asthma